一名遗传性血管性水肿患者从三种药物转换为使用lanadelumab-flyo治疗，该患者的基因存在变异：病例报告。
Transition to lanadelumab-flyo from three medications for a hereditary angioedema patient with a variant in the gene: A case report.
作者信息
Burns Stephanie, Lewis Elena
机构信息
Western Michigan University Kalamazoo MI USA.
Asthma Allergy Centers Portage MI USA.
出版信息
Clin Case Rep. 2021 Mar 20;9(4):2438-2441. doi: 10.1002/ccr3.4060. eCollection 2021 Apr.
Abstract
Non-SERPING1 gene variant hereditary angioedema patients often need to take progesterone, attenuated androgens, and antifibrinolytics to control symptoms. These drugs may need to be tapered to extinction or reduced as lanadelumab-flyo reaches maximum concentration.
摘要
非SERPING1基因变异型遗传性血管性水肿患者通常需要服用孕激素、减毒雄激素和抗纤维蛋白溶解剂来控制症状。随着lanadelumab-flyo达到最大浓度，这些药物可能需要逐渐减量直至停用或减少剂量。
Zotero 插件